-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$126.0026.04% Upside
Ligand Pharmaceuticals Incorporated Frequently Asked Questions
-
What analysts cover Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated has been rated by research analysts at RBC Capital, Craig-Hallum, H.C. Wainwright, Roth Capital in the past 90 days.